trending Market Intelligence /marketintelligence/en/news-insights/trending/wobi_ngn0nioYGtuMDqI-A2 content esgSubNav
In This List

Gene-therapy focused Genprex prices IPO

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Gene-therapy focused Genprex prices IPO

Genprex Inc. priced its IPO of between 2.5 million and 4.5 million shares on the Nasdaq Capital Market at $5 apiece.

The clinical stage gene therapy company — which would trade under the "GNPX" symbol will primarily use funds raised to continue developing its lung cancer drug Oncoprex which is currently in phase 2 trial.

The company expects the offering to close on Nov. 6 with Network 1 Financial Securities Inc. acting as its underwriter.